1.High-grade carcinoma in situ is an early stage cancer, which is second only to low-grade carcinoma in situ among cancers, so it is mild. 2.In-situ cancer is basically cured through surgery, and the recurrence rate is low. There is no need to be upset every day because of the word “cancer”. The surgical methods include total mastectomy, lumpectomy (whole breast radiotherapy is recommended after surgery) and breast-conserving surgery (whole breast radiotherapy is recommended after surgery). 3. According to the international and domestic guidelines for breast cancer diagnosis and treatment, radiotherapy is not needed after total mastectomy for in situ cancer. This is another proof that in situ cancer is a very mild cancer. The current medical evidence does not show that not playing chemotherapy will increase the risk of recurrence in the future. 4. c-erbB-2 is 3+ on the immunohistochemistry report, indicating that the molecular typing of this breast cancer is Her-2 (Her-2 is c-erbB-2) amplified breast cancer. This type of breast cancer usually requires biologic targeted therapy, i.e. biological treatment against the target of c-erbB-2 (Her-2), the name of the drug is Herceptin, which is expensive and needs to be used for 1 year with intravenous drip once every 21 days. There is not much evidence whether to perform biologic targeted therapy for carcinoma in situ, there are a few who advocate treatment, and most do not. My suggestion: if the financial condition is good and the patient does not have heart disease, then it can be considered. 5. Estrogen receptor and progesterone receptor are both negative (i.e. ER and PR are negative), which means that the effect of one of the most convenient and safest treatment methods for breast cancer is basically ineffective, i.e. endocrine therapy for breast cancer is ineffective. This is a great pity. I often compare this kind of treatment to the following situation: like a patient with “hypertension” who takes long-term antihypertensive drugs to control the disease for life, or a patient with “diabetes” who takes hypoglycemic drugs to control blood sugar.